Market Intelligence, Clinical Progress, and High-Purity Reagents for Cardiac Arrhythmia, Stroke, and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TRPM4 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Gene Delivery | TRPM4 Lentivirus Premade Particles Full-length ORF for stable cell line generation. HEK293T packaged, titer >10^8 TU/mL. Sequence Verified. |
View TRPM4 Products |
| Antigen (Mutant) | TRPM4 Disease Mutant Proteins Cardiac arrhythmia variants (e.g., E7K, R164W). HEK293 expressed. Theoretical MW verified. Endotoxin <1EU/µg. |
View TRPM4 Products |
| Benchmark Ab | Anti-TRPM4 (Reference Sequence) Recombinant rabbit monoclonal for flow cytometry validation. Sequence Verified. |
View TRPM4 Products |
| Validator | TRPM4 siRNA Set (3 unique sequences) For target specificity confirmation. Sequence Verified. |
View TRPM4 Products |
| Related Target A | TRPM5 Closest homolog (70% identity); Critical for off-target selectivity screening in taste signaling and pancreatic β-cells. |
View TRPM5 Products |
| Related Target B | SCN5A (Nav1.5) Complementary cardiac conduction pathway target; Co-expressed in sinoatrial node cells for combination safety studies. |
View SCN5A Products |
| Related Target C | TRPV4 Mechanosensitive channel partner in cardiovascular mechanotransduction; Alternative target in stroke pathophysiology. |
View TRPV4 Products |
| Related Target D | SUR1 (ABCC8) Co-assembles with TRPM4 under ischemia to form SUR1-TRPM4 complex; Key target for CNS injury drug design. |
View SUR1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Complex Membrane Topology (6-TM, Tetrameric) | Lentivirus for Stable Cell Line generation preserves native conformation; Essential for state-dependent binding assays. |
| TRPM4 vs TRPM5 Selectivity (70% Homology) | Ortholog Panel: Human TRPM4 and TRPM5 proteins strictly sequence-verified by mass spec for cross-reactivity elimination. |
| Calcium-Dependent Desensitization | Native glycosylation pattern (HEK293 expression) ensures proper trafficking and Ca²⁺-sensitive gating behavior. |
| Channelopathy Variant Validation | Cardiac disease mutants available (Progressive Familial Heart Block Type 1 variants); Sequence Verified for structure-function studies. |
| False Positives in Calcium Imaging | Validated siRNA sets included for target engagement confirmation; Negative controls available. |
Live TRPM4 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TRPM4 therapeutics is intensifying, with major players shifting focus from traditional ion channel blockers to state-dependent modulators and monoclonal antibodies targeting extracellular domains. First-generation small molecules (Sanofi, Merck legacy programs) faced selectivity challenges against TRPM5. A notable clinical example is Biogen's intravenous glibenclamide (BIIB093) for large hemispheric infarction, which targets the SUR1-TRPM4 complex upregulated in ischemia. The next wave of R&D is targeting cardiac-specific isoforms for arrhythmias, stroke neuroprotection where calcium dysregulation drives pathology, and prostate cancer where TRPM4 is implicated in tumor progression.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Inhibitor | Sanofi, Evotec, Biogen, Academic Consortia | Cardiac Arrhythmias (PFHB1), Stroke | Automated Patch Clamp on Stable Cell Lines (Need full-length Lentivirus expression) |
| Monoclonal Antibody | Emerging Biotechs (Undisclosed) | Immuno-oncology, Prostate Cancer, Autoimmunity | Extracellular Domain Binding (Need properly folded membrane-inserted target or ECD-Fc proteins) |
| Antisense Oligonucleotide | Ionis (Preclinical exploration) | Cardiac Conduction Disorders | Precise Target Validation (Need siRNA controls and knockdown validation) |
| Allosteric Modulator | Biovista, AI-driven Discovery | Neurodegeneration | Calcium Flux Assays (Need native glycosylation for proper channel function) |
Molecular Differentiation & Assay Strategy
Key Differentiation Factors:
- Selectivity vs TRPM5 (70% homology): Best-in-class drugs must avoid off-target effects on TRPM5 to prevent taste loss and metabolic disruption.
- Conformation dependency: State-dependent binding (open vs closed channel) requires proper membrane topology; complex with SUR1 in CNS injury provides a unique pathological target.
- Calcium sensitivity: Ca²⁺-calmodulin interaction must be preserved for physiological activation; native glycosylation is critical.
- Cardiac safety: Cross-screen against hERG, SCN5A, and native TRPM4 to avoid conduction abnormalities.
Recommended Screening Cascade:
- Primary: Calcium flux (FLIPR/FDSS) using TRPM4 stable cell line.
- Secondary: Automated patch-clamp (e.g., SyncroPatch 384PE) for IC50 and kinetic analysis.
- Counter-screening: Parallel testing on TRPM5 and SUR1-TRPM4 co-expressing cells.
- Validation: siRNA knockdown to confirm on-target specificity.
TarMart Advantage:
- High-titer Lentivirus particles for constructing stable cell lines with native 6-TM tetrameric conformation.
- Disease mutation variants (PFHB1: E7K, R164W, etc.) available for structure-function studies.
- Sequence-verified benchmark antibodies and siRNA sets ensure reliable assay controls.